X

Trial Profile

A Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Advanced Solid Tumors and Metastatic Brain Cancer (ANG1005-CLN-02).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel trevatide (Primary)
Indications Brain metastases; Solid tumours
Focus Adverse reactions
Sponsors AngioChem

Most Recent Events

15 May 2014 According to the Angiochem media release, the clinical data from this trial presented at the American Society of Clinical Oncology (ASCO) 50th Annual meeting May 30-June 3, 2014 in Chicago, IL.
09 Jun 2010 Changes: added actual pt number 56
09 Jun 2010 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com